Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies

Role of the Human High-Affinity Copper Transporter in Copper Homeostasis Regulation and Cisplatin Sensitivity in Cancer Chemotherapy

(2012) M. T. Kuo et al.   CANCER RESEARCH

Overcoming Platinum Resistance through the Use of a Copper-Lowering Agent

(2012) Siqing Fu et al.   MOLECULAR CANCER THERAPEUTICS

Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents

(2012) Z. D. Liang et al.   MOLECULAR CANCER THERAPEUTICS

Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy

(2011) Helen H.W. Chen et al.   LUNG CANCER

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

(2010) Siqing Fu et al.   CANCER

Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator

(2010) Seiko Ishida et al.   CANCER CELL

Overcoming platinum resistance in ovarian carcinoma

(2010) Koji Matsuo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Triethylenetetramine Pharmacology and Its Clinical Applications

(2010) J. Lu   MOLECULAR CANCER THERAPEUTICS

Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs

(2010) S. B. Howell et al.   MOLECULAR PHARMACOLOGY

Novel strategies for reversing platinum resistance

(2009) Mian M.K. Shahzad et al.   DRUG RESISTANCE UPDATES

Mechanistic Comparison of Human High-Affinity Copper Transporter 1-Mediated Transport between Copper Ion and Cisplatin

(2009) Z. D. Liang et al.   MOLECULAR PHARMACOLOGY

Treatment of Wilson's disease with tetrathiomolybdate: V. control of free copper by tetrathiomolybdate and a comparison with trientine

(2009) George J. Brewer et al.   Translational Research

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer

(2008) Franco Muggia   GYNECOLOGIC ONCOLOGY

A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer

(2008) Elaina M. Gartner et al.   INVESTIGATIONAL NEW DRUGS

Elevated Glutathione Levels Confer Cellular Sensitization to Cisplatin Toxicity by Up-Regulation of Copper Transporter hCtr1

(2008) H. H. W. Chen et al.   MOLECULAR PHARMACOLOGY

Mechanisms for copper acquisition, distribution and regulation

(2008) Byung-Eun Kim et al.   Nature Chemical Biology